ライフサイエンスコーパス: peptidomimetic

1 th c(RGDfK), a well-studied integrin-binding peptidomimetic.

2 ne and side chain torsion angles for a model peptidomimetic.

3 ning and refining therapeutically-attractive peptidomimetics.

4 al properties of this peptide by introducing peptidomimetics.

5 tives are valuable pharmacological agents as peptidomimetics.

6 e introduced as the backbone modification in peptidomimetics.

7 development of new small antiviral drugs or peptidomimetics.

8 nthesis of biologically active molecules and peptidomimetics.

9 advantage of peptoids over other families of peptidomimetics.

10 ioisostere to provide protease resistance in peptidomimetics.

11 ess to obtain the linear C-hydroxyalkylamido peptidomimetics.

12 synthesized and assayed libraries of mutant peptidomimetics.

13 ng conformationally constrained beta-hairpin peptidomimetics.

14 r-Psi[(Z and E)CH=C]-Pro-Arg-NH(2), 1 and 2, peptidomimetics.

15 rious ligands including TRP/NTL peptides and peptidomimetics.

16 moieties were placed at opposite ends of PLG peptidomimetic 1 to generate a series of ligands that po

17 g at the same allosteric site as PLG and PLG peptidomimetic 1.

18 hesized on the basis of the gamma-lactam PLG peptidomimetic 1.

19 We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaff

20 A tetrazole-based peptidomimetic 2 (BMS-317180) was discovered as a human

21 deprotection provided the epoxide-containing peptidomimetics, 4 and 5.

22 Bicyclic peptidomimetic 7 and spirobicylic peptidomimetic 8 enhan

23 Bicyclic peptidomimetic 7 and spirobicylic peptidomimetic 8 enhanced the binding of [3H] N-propylno

24 This can be exploited by the BH3 peptidomimetic ABT737, through non-BCL-2-dependent synth

25 A peptidomimetic ADAM8 inhibitor, BK-1361, designed by str

26 lphavbeta3)) and microbubbles coupled to the peptidomimetic agent c(RGDfK) (MB(cRGD)).

27 Hsp90 targeting using a cell-permeable peptidomimetic agent resulted in marked attenuation of n

28 l pain conditions and to test potency of the peptidomimetic agonists in vivo, we evaluated these agon

29 All peptidomimetic agonists stimulated PAR(2)-dependent in v

30 The anti-p185(her2/neu) peptidomimetic (AHNP) is a small exo-cyclic peptide deri

31 y of conformationally restrained dipeptides, peptidomimetics, alkaloids, and other biologically activ

32 Small RGD-based peptidomimetic alpha(v)beta(3) antagonists significantly

33 Small peptidomimetic alphavbeta3 integrin antagonists dramatic

34 Mice treated with the SOCS1 peptidomimetic also exhibited reduced kidney leukocyte r

35 coated either with an alphavbeta3-selective peptidomimetic, an alpha5beta1-selective peptidomimetic,

36 To test this hypothesis, peptidomimetic analogues 3-5, which have either an N-hyd

37 We now report four peptidomimetic analogues, compounds 6-9, which are ratio

38 mbly of a diverse collection of silane-based peptidomimetic analogues.

39 ign is important for the development of this peptidomimetic and for its anti-angiogenic effects.

40 is for developing gp120 dual inhibitors into peptidomimetic and increasingly smaller molecular weight

41 Aspartic protease inhibitors (peptidomimetic and natural product), calpain inhibitors,

42 ovides structural rigidity within the cyclic peptidomimetic and promotes the creation of a stabilizin

43 458 binding was saturatable, displaceable by peptidomimetic and small molecule gamma-secretase inhibi

44 gamma-secretase, SPP is inhibited by helical peptidomimetics and apparently contains a substrate-bind

45 hput synthesis of linear C-hydroxyalkylamido peptidomimetics and beta-turn cyclic peptidomimetics via

46 es a concrete basis for the design of potent peptidomimetics and nonpeptidic compounds to inhibit MLL

47 The peptidomimetics and pyrimidoindolones bind to both activ

48 -HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to thi

49 derived from the C-terminal tail of FGF23 or peptidomimetics and small-molecule organomimetics of the

50 of rhodesain inhibitors, including peptidic, peptidomimetic, and nonpeptidic structures, emphasizing

51 phoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A).

52 n selectively targeted with the bisaryl urea peptidomimetic antagonist 1.

53 Structural optimization of a peptidomimetic antagonist of formyl peptide receptor 2 (

54 resent good candidates for further design of peptidomimetic antagonists capable of blocking the fusio

55 We show that actinonin, a peptidomimetic antibiotic that inhibits HsPDF, also inhi

56 t access to potential proline surrogates for peptidomimetic applications.

57 Herein, we describe a peptidomimetic approach that increases the stability of

58 Non-natural antimicrobial peptidomimetics are an ideal example of this, as they ha

59 Peptidomimetics are classes of molecules that mimic stru

60 Thiazolino fused 2-pyridone peptidomimetics are of significant biological importance

61 Peptidomimetics are small protein-like molecules designe

62 ligohydrazide (azatide) fragments into their peptidomimetic arms to reduce hydrophobicity and increas

63 e infusion of PF4 or PF4-related peptides or peptidomimetics as a way of beneficially stimulating "en

64 ion toward the design of cyclic peptides and peptidomimetics as calpain inhibitors.

65 nactive peptide, administration of the SOCS1 peptidomimetic at either early or advanced stages of dia

66 fluoromethyl aldimines, small psi[CH(CF3)NH]-peptidomimetic backbones can be achieved in which a new

67 CB-TE1A1P-PEG4-LLP2A), a high-affinity VLA-4 peptidomimetic-based radiopharmaceutical, was evaluated

68 crown-6 (18C6) affinities of nine protonated peptidomimetic bases are determined using guided ion bea

69 tics for neutral and protonated 18C6 and the peptidomimetic bases, as well as the proton bound comple

70 tests the hypothesis that the conjugation of peptidomimetic beta-secretase inhibitors with a fragment

71 olds that are structurally distinct from the peptidomimetic BIIE0246.

72 proapoptotic agent bone metastasis-targeting peptidomimetic (BMTP-11) in preclinical models of primar

73 nalyses revealed that the most potent cyclic peptidomimetic bound to the iNOS binding site of SPSB2 w

74 ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specifi

75 ionally restricted beta-sheet breaker hybrid peptidomimetics (BSBHps).

76 Herein, we report the synthesis of peptidomimetic building blocks containing backbone-fluor

77 viously discovered anti-alphaVbeta3 integrin peptidomimetic (c(AmpRGD)) and the clinically approved a

78 2 interaction with Plk1-PBD was blocked by a peptidomimetic called 103-8.

79 in the low micromolar range, rivaling other peptidomimetic calpain inhibitors and presenting an impr

80 meostasis, and we suggest that ANXA1 and its peptidomimetics can be novel therapeutic targets in neur

81 Since phage-borne peptidomimetics can be selected from phage display libra

82 Peptides or peptidomimetics can mimic binding of the tethered ligand

83 Synthetic peptidomimetic chemistry is a powerful tool for creating

84 HIV-1 virus replication inhibitors based on peptidomimetic chemistry.

85 o the surfaces and the alphavbeta3-selective peptidomimetic-coated nanotopographies promoted osteogen

86 leads to (i) a chemical library of putative peptidomimetics combining diverse azaheterocycles with t

87 This work helps address the peptidomimetic community's need for an automated and exp

88 rin extracellular fragment in complex with a peptidomimetic compound that was previously shown to par

89 C-MyoA peptidomimetic compounds that disrupt the MTIP-myosin A

90 r the rational design of specific and potent peptidomimetic compounds that may be useful for the trea

91 of the BCL-2 family of proteins, we designed peptidomimetic compounds using a benzoylurea scaffold to

92 We introduce a family of multivalent peptidomimetic conjugates that modulate the activity of

93 We have studied the efficacy of BH3 peptidomimetics consisting of the minimal death, or BH3,

94 latelets are less responsive to peptides and peptidomimetics containing an arginine-glycine-aspartic

95 n Ugi four-component reaction generating the peptidomimetic core structure.

96 TTT-28, a newly synthesized thiazole-valine peptidomimetic, could reverse ABCB1-mediated MDR in vitr

97 Although typically less potent than their L-peptidomimetic counterparts, selected all D-amino acid c

98 be very valuable in the development of novel peptidomimetic CXCR4 antagonists.

99 gn and further development of small-molecule peptidomimetic CXCR4 antagonists.

100 such as PELP1 using a novel, small molecule peptidomimetic (D2).

101 The peptidomimetics described herein comprise a dibenzofuran

102 tor conformations suitable for computational peptidomimetic design, and that inclusion of disordered

103 point for structure-based small molecule and peptidomimetic drug development.

104 rocyclic HIV-1 antagonists as a new class of peptidomimetic drug leads.

105 ce for the development of other peptidic and peptidomimetic drugs such as inhibitors of the blood clo

106 ts for SAR campaigns, integral components of peptidomimetic drugs, and potential drugs on their own.

107 evelopment has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like propertie

108 orption of dipeptides, tripeptides, and many peptidomimetic drugs.

109 Intermolecular stacking of the collapsed peptidomimetics, enabled by intermolecular hydrogen bond

110 etic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibi

111 unique, selective, and potent small molecule peptidomimetic, FISLE-412, which neutralizes anti-dsDNA/

112 e mediated hydrolysis enabled preparation of peptidomimetic fluorophores with useful photophysical pr

113 toids are an increasingly important class of peptidomimetic foldamers comprised of N-alkylglycine uni

114 Aliphatic N,N'-linked oligoureas are peptidomimetic foldamers that adopt a well-defined helic

115 armacology, thus prompting the design of new peptidomimetic foldamers.

116 h was followed by amino acids, peptides, and peptidomimetics for medicinal chemistry.

117 This approach may yield reagents such as peptidomimetics for novel diagnostic and therapeutic int

118 aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytoto

119 e present the synthesis of highly active RGD peptidomimetics for the alphavbeta3 integrin with remark

120 ve recently emerged as important examples of peptidomimetics for their interesting complexing propert

121 This peptidomimetic/free radical system is a potentially exce

122 Optimization of our previously described peptidomimetic furin inhibitors was performed and yielde

123 be potentiated by NO signaling, therefore, a peptidomimetic furoxan was tested in hippocampal slices

124 ied as a common binding site for peptide and peptidomimetic fusion inhibitors.

125 netic properties of a novel class of achiral peptidomimetic HCV NS3 protease inhibitors.

126 ethod can be used to prepare imidazole based peptidomimetics, herein exemplified by the synthesis of

127 s and provides a guide for further design of peptidomimetic HIV-1 inactivators based on the PT pharma

128 Peptidic and peptidomimetic hydroxamates are increasingly being devel

129 gets for anticancer therapy, and a number of peptidomimetic IAP antagonists have entered clinical tri

130 clodehydration to afford thiazole containing peptidomimetics in a short synthetic sequence.

131 ation of co-crystal structures of two potent peptidomimetics in complex with WDR5 establishes their s

132 g in a single process generating the desired peptidomimetics in good to excellent yields within a 25

133 beta-Strand peptidomimetics incorporating amino acid analogues based

134 On the basis of the results, a peptidomimetic inhibitor (compound 1) was designed and y

135 )(2) (2) was prepared from the nitrile-based peptidomimetic inhibitor Ac-Phe-NHCH(2)CN (1).

136 The structure of HsPDF bound to the peptidomimetic inhibitor actinonin (1.7 A) identified th

137 y demonstrated the eutomer (3S,5R)-5 to be a peptidomimetic inhibitor binding to a nonsubstrate topog

138 omplex formation and provides guidelines for peptidomimetic inhibitor design.

139 east cancer cells, and targeting BCL6 with a peptidomimetic inhibitor leads to apoptosis of these cel

140 ear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decrease

141 -principle, we developed a small, selective, peptidomimetic inhibitor of Ena/VASP EVH1 domain interac

142 escribe the design of a potent and selective peptidomimetic inhibitor of geranylgeranyltransferase I

143 VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV)

144 t attachment of a phosphonic acid motif to a peptidomimetic inhibitor scaffold.

145 d that zinc ion and a Michael acceptor-based peptidomimetic inhibitor synergistically inactivate FIPV

146 show that 19a is a novel potential antitumor peptidomimetic inhibitor that can be used as a starting

147 was found to be as potent as OM00-3, a known peptidomimetic inhibitor, 4-fold more selective toward b

148 e specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and

149 ion of Escherichia coli PDF by a macrocyclic peptidomimetic inhibitor.

150 y to enhance the efficacy of an irreversible peptidomimetic inhibitor.

151 ing studies were conducted using a series of peptidomimetic inhibitors (compounds 1-6, Table 3) and t

152 molecular dynamics to model structures of 12 peptidomimetic inhibitors bound to the SH2 domain of STA

153 he dominant interface with small molecule or peptidomimetic inhibitors could specifically prevent act

154 ts of HIV-1 protease over those of the other peptidomimetic inhibitors currently on the market.

155 Of the peptidomimetic inhibitors of APA, amastatin has higher p

156 nticoagulants, a series of potent, selective peptidomimetic inhibitors of FXIa were designed and synt

157 Peptidomimetic inhibitors of HIV-1 PR are still a key re

158 pathways predictive of tumors responsive to peptidomimetic inhibitors of its 20S core protease activ

159 Peptidomimetic inhibitors of MERS-CoV 3CL(pro) were synt

160 Although several peptidomimetic inhibitors of NS3 protease have been publ

161 ign, synthesis, and evaluation of reversible peptidomimetic inhibitors of Plm II as potential antimal

162 The mode of inhibition for phosphoramidate peptidomimetic inhibitors of prostate-specific membrane

163 streamlined approach for discovering potent peptidomimetic inhibitors of protein-protein interaction

164 the design of Src homology 2 (SH2) directed peptidomimetic inhibitors of Stat3, in this paper we des

165 ied the factors affecting the selectivity of peptidomimetic inhibitors of the highly homologous prote

166 a novel series of potent and cell permeable peptidomimetic inhibitors of the human beta-secretase (B

167 have designed a class of potent macrocyclic peptidomimetic inhibitors of the menin-MLL1 interaction.

168 were used to design specific methyleneamino peptidomimetic inhibitors of the plasmepsins.

169 n, synthesis, and characterization of cyclic peptidomimetic inhibitors of the SPSB2-iNOS interaction

170 y have been exploited in discovering related peptidomimetic inhibitors of the Tat-TAR interaction in

171 s problem, we sought to identify constrained peptidomimetic inhibitors that would provide potential n

172 nd its complexes with angiotensin IV and the peptidomimetic inhibitors, amastatin and bestatin.

173 Phosphotyrosine-based peptidomimetic inhibitors, which mimic pTyr-Xaa-Yaa-Gln

174 uture structure-based design of non-covalent peptidomimetic inhibitors.

175 A radiolabeled peptidomimetic integrin antagonist, (111)In-DOTA-IA, was

176 ugh binding to the neonatal Fc receptor, the peptidomimetic introduces cross-species binding to cell

177 The peptidomimetic is shown to adopt a well-defined beta-hai

178 polyhydroxylated piperidine and pyrrolidine peptidomimetics is described.

179 amino acid as the central core and acting as peptidomimetics, is presented.

180 with three different classes of inhibitors: peptidomimetics, isatins, and pyrimidoindolones.

181 hancement of the therapeutic effect over the peptidomimetic itself in animal models of breast cancer

182 relationships (SAR) offer a way to establish peptidomimetic libraries.

183 (LLP2A) is a high-affinity, high-specificity peptidomimetic ligand (inhibitory concentration of 50% =

184 ching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin alpha4bet

185 PEG4-LLP2A ([(64)Cu]-LLP2A), a high affinity peptidomimetic ligand for very late Ag-4 (VLA-4; also ca

186 rmacological delivery of a soluble ephrin-A1 peptidomimetic ligand led to a reduction in EphA2 expres

187 This study investigates whether CN2097, a peptidomimetic ligand which targets the synaptic scaffol

188 luated 2 conjugates of a high-affinity VLA-4 peptidomimetic ligand, LLP2A, for PET/CT imaging in a su

189 Hence, we reasoned that lipidation of peptidomimetic ligands could promote membrane targeting

190 wide variety of conformationally restricted peptidomimetic linkers at the point of juncture.

191 To efficiently design a peptidomimetic, local constraints must be introduced int

192 ynthesis of a range of highly functionalized peptidomimetic macrocycles has been accomplished using r

193 trategy for synthesizing passively permeable peptidomimetic macrocycles.

194 inoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacological pro

195 ogen receptor-coregulator interactions using peptidomimetics may be a viable therapeutic approach for

196 type of proteolytically stable FPR2-specific peptidomimetics may serve as valuable tools for future a

197 The most potent macrocyclic peptidomimetic (MCP-1), 34, binds to menin with a K(i) v

198 Evaluation of one such peptidomimetic, MM-102, in bone marrow cells transduced

199 ed drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 is

200 resentative of a new class of PSMA targeting peptidomimetic molecules that shows great promise as ima

201 tides are emerging as an attractive class of peptidomimetic molecules.

202 The latter may be a peptidomimetic monoclonal antibody (MAb) to the transfer

203 r Trojan horse, which is a second peptide or peptidomimetic monoclonal antibody that binds a specific

204 r group chemically modified an antimicrobial peptidomimetic motif for targeted applications against c

205 lls are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer c

206 Recently, peptidomimetic N,N'-linked oligourea helices have been d

207 array comprising different types of cationic peptidomimetics obtained by a general monomer-based soli

208 A peptidomimetic of Pro-Leu-Pro-NH2, 7, possessing an indo

209 We delivered dPGS-PTX in combination with a peptidomimetic of the anti-angiogenic protein thrombospo

210 Two epoxide-containing peptidomimetics of the isopeptide, glutamyl-gamma-glutam

211 Conformationally ordered peptidomimetic oligomers are finding broad applications

212 Peptidomimetic oligomers can frequently be synthesized u

213 atility and ease of structural modification, peptidomimetic oligomers have not yet been explored exte

214 hibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.

215 lecule for the preparation of collections of peptidomimetics or biologically active compounds based o

216 ive peptidomimetic, an alpha5beta1-selective peptidomimetic, or an RGD/PHSRN peptidic molecule.

217 inal heptapeptide, P7 (Ac-1FTLDADF7) and its peptidomimetic P6 (1Fmoc(Me)PhgLDChaDF7) bound to Saccha

218 STLs contained a peptidomimetic PAR(2) agonist (2-aminothiazol-4-yl-LIGRL

219 2) (2-f-LIGRLO-NH(2)) underscores the use of peptidomimetic PAR(2) ligands as a mechanism to enhance

220 Structure-affinity studies led to the peptidomimetic, pCinn-Haic-Gln-NHBn (21), which had an I

221 These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcoma

222 outes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy.

223 ttractive intermediates for the synthesis of peptidomimetics, polyheterocycles, and other multifuncti

224 Most of the peptidomimetics possessed high to moderate activity towa

225 The higher binding affinity of the peptidomimetic presumably reflects the effect of constra

226 Here, we describe how small peptide and peptidomimetic probes derived from the lipid binding dom

227 Evaluation of these peptidomimetic prodrugs in a growth inhibition assay and

228 date derivatives of TFV should be considered peptidomimetic prodrugs of TFV.

229 s an important strategy for the synthesis of peptidomimetics (pseudo-peptides).

230 tems in Lepidoptera and aid in the design of peptidomimetics, pseudopeptides or small molecules capab

231 ch to a novel class of falcipain inhibitors: peptidomimetic pyrimidine nitriles.

232 hat 6 out of all 8 possible stereoisomers of peptidomimetic pyrrolidines can be obtained in good yiel

233 Peptidomimetics represent an important field in chemistr

234 Incorporation of unnatural amino acids and peptidomimetic residues into therapeutic peptides is hig

235 pha/beta, alpha/gamma and alpha/delta hybrid peptidomimetics, respectively.

236 A series of opioid analogues with a common peptidomimetic scaffold displayed remarkable inversions

237 iety of highly substituted lactam containing peptidomimetic scaffolds are prepared by solid-phase syn

238 Moreover, this peptidomimetic selectively interferes with the integrity

239 that, through N-acetylation of our original peptidomimetic series, we are able to improve DOR affini

240 In a previously described peptidomimetic series, we reported the development of bi

241 ign, synthesis, and biological evaluation of peptidomimetic severe acute respiratory syndrome chymotr

242 ex with PBP 5 in complex with a boronic acid peptidomimetic shows that the position corresponding to

243 nd evaluated the therapeutic efficacy of the peptidomimetic small molecule ICG-001, which specificall

244 t the poor mimicry of the amide bond by many peptidomimetics stems from their inability to partake in

245 Therefore, a new peptidomimetic strategy, referred to as fragment hopping

246 The peptidomimetic structure was synthesized by solid-phase

247 of drugs as they accept a large spectrum of peptidomimetics such as beta-lactam antibiotics, antivir

248 (Hydroxyethyl)urea peptidomimetics systematically altered at positions P2-P

249 ptides is a means to begin accessing complex peptidomimetics systematically.

250 Thus, peptidomimetic targeting of transcription factor fusion

251 search for effective cationic antimicrobial peptidomimetics targeting specific bacteria.

252 g two additional residues and the beta-sheet peptidomimetic template "Hao".

253 MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing comple

254 he Win motif-WDR5 interaction, we designed a peptidomimetic that binds WDR5 (Kd approximately 3 nm) a

255 gated it to an electrophilic derivative of a peptidomimetic that binds with high affinity and specifi

256 ion with new or approved beta-lactams, and a peptidomimetic that have entered full clinical developme

257 ared with cilengitide, an integrin-targeting peptidomimetic that performed poorly in recent clinical

258 Herein, we review recent developments in peptidomimetics that are formed via heteroatom replaceme

259 -AApeptides are a new class of antibacterial peptidomimetics that are not prone to antibiotic resista

260 describe Neoseptins, chemically synthesized peptidomimetics that bear no structural similarity to th

261 to focus our attention on short peptides or peptidomimetics that behave as LMWGs.

262 gn, synthesis, and evaluation of macrocyclic peptidomimetics that bind to WD repeat domain 5 (WDR5) a

263 menable to the development of small molecule peptidomimetics that could be used to modulate NER repai

264 ar weight drugs against NS3-4A are substrate peptidomimetics that have a similar binding and resistan

265 n order to obtain gold(III)-based anticancer peptidomimetics that might specifically target two pepti

266 A series of beta-diketone derivatives of RGD peptidomimetics that selectively bind to alphavbeta3 and

267 he development of D-enantiomer antimicrobial peptidomimetics that target bacterial membranes of certa

268 be taken into account in designing potential peptidomimetics that target P. gingivalis adherence and

269 date prodrugs (8-10) of phosphate-containing peptidomimetics that target the SH2 domain were synthesi

270 ibody and phage particles bearing a molinate peptidomimetic, the EI performed with an IC(50) of 0.15

271 Similar to peptides and other peptidomimetics, these well-defined synthetic macromolec

272 ssess several features that are desirable in peptidomimetics; they are easily synthesized, fold into

273 otective antibodies may facilitate design of peptidomimetics to focus vaccine responses on protective

274 We report herein the capacity of sugar-based peptidomimetics to inhibit both Abeta1-42 early oligomer

275 present study, we designed a large number of peptidomimetics to target the MLL1/WDR5 interaction base

276 ylamido peptidomimetics and beta-turn cyclic peptidomimetics via "volatilizable" aminoalkyl functiona

277 cological tools, the effect of a short AnxA1 peptidomimetic was tested.

278 ransferase, a series of imidazole-containing peptidomimetics was designed and synthesized, and their

279 structural variation of these antibacterial peptidomimetics was investigated as a tool for optimizin

280 Taurine-containing water-soluble peptidomimetics were designed and synthesized.

281 Beta-turn cyclic peptidomimetics were generated by intramolecular S(N)Ar

282 Both the linear and the cyclic peptidomimetics were obtained with good to excellent yie

283 A series of vinyl sulfone-containing peptidomimetics were rationally designed, synthesized, a

284 The peptidomimetics were used at very low concentrations (10

285 of the inhibitors that are on the market are peptidomimetics, where a conserved water molecule mediat

286 of this Pauli repulsion by employing common peptidomimetics, wherein the n --> pi* interaction is at

287 completely new, previously unknown family of peptidomimetics, which are hydrolytically stable and dis

288 Our study led to the design of high-affinity peptidomimetics, which bind to WDR5 with K(i) < 1 nM and

289 ysis of a novel class of heteroatom-modified peptidomimetics, which we shall call "oxyazapeptides".

290 affold was used for the preparation of model peptidomimetics, whose beta turn conformation was confir

291 characterization of this new thiazole-valine peptidomimetic will facilitate design and synthesis of a

292 and creating a backbone cyclic beta-hairpin peptidomimetic with 80-fold higher affinity for the Fc d

293 hermore, optimization of the length of these peptidomimetics with an alternating cationic-hydrophobic

294 rovided two pairs of Pro-Leu-Gly-NH(2) (PLG) peptidomimetics with contrasting dopamine receptor modul

295 f Mfa1 and SspB and suggest that peptides or peptidomimetics with greater specific inhibitory activit

296 Peptoids constitute a class of peptidomimetics with potential as protease resistant, bi

297 Low molecular weight peptidomimetics with simple amphiphilic sequences can he

298 c compounds 1b and 3b provided the first PLG peptidomimetics with the ability to decrease the binding

299 on, and conformational analysis of the first peptidomimetics with two pendant, chiral nitronyl nitrox

300 Ala mutation and covalently inactivated by a peptidomimetic (ZLLYCH2F) at 2.0 A resolution.